On Monday, the XRP Ledger recorded transfers worth $49.66 billion, representing 60.4% of XRP's total market value. However, this figure reflects all movements between addresses, not actual trades, as only $1.47 billion changed hands on exchanges. The low network fees of $664 for these transfers indicate that most movements were internal reshuffles rather than genuine buying activity. Meanwhile, XRP's price hovered around $1.30, with exchange reserves hitting a local high, and US spot ETFs experienced a small outflow, signaling cautious market sentiment. Investors should focus on spot turnover and exchange reserves rather than transfer volume to gauge true demand.
The XRP Ledger's transfer volume reached $49.66 billion, representing 60.4% of XRP's total market value, with network fees totaling only $664. For readers following the broader cryptocurrency market, here is Pluang's snapshot as of Oct 20, 2026 01:32 WIB: out of 50 major cryptocurrencies, 41 rose and 8 fell. Notable movers include ATOM (Cosmos) with a 5.56% gain and 76% buy order activity, EGLD (MultiversX) up 3.86% with 57% buy orders, and SUSHI (SushiSwap) rising 3.60% with a 55% sell order activity and a typical hold time of 102 days on Pluang.
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
On October 19, 2026, several stocks saw significant declines. Iambic Therapeutics dropped 31.4% but stayed just above its IPO price of $16 after raising $150 million. TCGX Acquisition fell 18.5% following its announcement of a merger with TriGemX Bio...
